Tuesday 24 July 2018

---

Kypha, a US medical diagnostics company, developing specialised biomarker testing solutions for precision monitoring of immune status and inflammation, has acquired Biosensia, an Irish diagnostics platform and contract development company, to strengthen Kypha's product portfolio. Biosensia, established in 2009, is headquartered at NovaUCD, the Centre for New Ventures and Entrepreneurs at University College Dublin, and will continue to operate as a wholly owned subsidiary of Kypha.

Universally accessible, reliable and timely immune status results

---

This acquisition demonstrates Kypha's commitment to meet the need for universally accessible, reliable and timely immune status results in virtually any setting from acute hospital care, to centralised laboratories, physician offices and home use. The combined first-in-class platforms promise to quickly and accurately detect meaningful changes in immune-mediated disease activity for more effective treatment decisions and patient care. Kypha's innovative diagnostics platforms measure Complement and other important immune status biomarkers accurately, and reliably. Kypha's Comp act® testing platform, analytically validated and GMP-manufactured, includes a small portable instrument with multiple single-use rapid assay cassettes designed to quantitatively measure Complement activation biomarkers, from a small volume of blood in either laboratory or point-of-care settings. Biosensia's RapiPlex is a proprietary diagnostic system designed to support CLIA-waived protocols and is capable of producing laboratory quality quantitative and qualitative results with a disposable cartridge for up to 24 biomarkers in a multiplex format. Dr Chad Stiening, Kypha CEO, said: "The proprietary technologies and core competencies of each company are perfectly synergistic. Blending them enhances and accelerates the delivery of our products to health care practitioners, researchers and pharmaceutical companies seeking to more precisely assess and monitor immune status dynamics.

Provide contract assay development and manufacturing services

---

"The addition of Biosensia's EU-based ISO-certified facilities and deeply experienced core team allows us to bring product development, quality control and test manufacturing in house and continue to provide contract assay development and manufacturing services to Biosensia clients around the world." Niamh O'Luanaigh, chief operating officer, Biosensia, said: "We are very excited about bringing our advanced platform together with Kypha's specialised biomarker testing and achieving the clinical impact that we designed RapiPlex to fulfil. “This is a fantastic development for Biosensia and recognises the hard work and dedication of our highly skilled team which we now plan to expand following the acquisition by Kypha." Dr Martin Schmidt, chief scientific officer, Kypha, said: "With continued growth in biologic and cellular therapies targeting Complement and immune-mediated mechanisms, the need for these solutions is growing rapidly. "This acquisition reinforces our position as the ideal diagnostic partner for stratifying patient populations and tailoring treatment for each patient suffering from immune mediated conditions." Biosensia has been funded by Atlantic Bridge, Seroba Life Sciences, ACT Venture Capital, Street Capital and a number of private investors.